Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | Z003401 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y017914 | — |
No additional AE reported; Physician assistant reported that a patient received MMR II on 12/19/2025 and VARIVAX on 12/26/2025. No additional AE/No PQC reported.; This spontaneous report was received from an Other health professional (physical assistant) and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 19-Dec-2025, the patient was vaccinated with 1 dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), lot #Z003401, expiration date: 23-Jan-2027 (exact dose, route of administration and anatomical location were not provided) for prophylaxis. The vaccine was reconstituted with 1 dose of sterile diluent (Hollister-Stier STERILE DILUENT) (lot # and expiration date were not reported). On 26-Dec-2025, the patient was vaccinated with 1 dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), lot #Y017914, expiration date: 28-Oct-2026) (exact dose, route of administration and anatomical location were not provided) for prophylaxis (inappropriate schedule of product administration). No additional adverse event reported (no adverse event).
DILUENT MRK